Review



shrna constructs against mouse src  (OriGene)


Bioz Verified Symbol OriGene is a verified supplier
Bioz Manufacturer Symbol OriGene manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    OriGene shrna constructs against mouse src
    Figure 3. mSH3BGRL activates MAPK and AKT pathways in an FAK-dependent manner. (a) Lysates from stable cell lines were incubated with GST-Raf to enrich for GTP-bound active Ras. Eluates and total lysates were subsequently immunoblotted with various Ras/MAPK pathway-specific antibodies. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) served as a loading control. (b) Lysates from (a) were immunoblotted with anti-p-FAK Y576/577 or FAK antibodies. (c) Lysates prepared as in (a) were incubated with GST-PBD (to enrich for GTP-bound active Cdc42 and Rac1). Elutes and total lysates were subsequently immunoblotted with antibodies against Cdc42 and Rac1. (d) CT-26 Vec, <t>CT-26</t> <t>SH3BGRL,</t> CHO Vec and CHO SH3BGRL cells were transfected with FAK-specific <t>siRNA,</t> where indicated, for 48 h and lysed. Lysates were immunoblotted with the various antibodies listed. GAPDH was served as a loading control. The averaged relative protein expression level is quantified and shown under the immediate panels.
    Shrna Constructs Against Mouse Src, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/shrna+constructs+against+mouse+src/Src+Mouse+shRNA+Plasmid/pm26455318-157-10-15
    Average 90 stars, based on 1 article reviews
    shrna constructs against mouse src - by Bioz Stars, 2026-10
    90/100 stars

    Images

    1) Product Images from "Dual-faced SH3BGRL: oncogenic in mice, tumor suppressive in humans."

    Article Title: Dual-faced SH3BGRL: oncogenic in mice, tumor suppressive in humans.

    Journal: Oncogene

    doi: 10.1038/onc.2015.391

    Figure 3. mSH3BGRL activates MAPK and AKT pathways in an FAK-dependent manner. (a) Lysates from stable cell lines were incubated with GST-Raf to enrich for GTP-bound active Ras. Eluates and total lysates were subsequently immunoblotted with various Ras/MAPK pathway-specific antibodies. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) served as a loading control. (b) Lysates from (a) were immunoblotted with anti-p-FAK Y576/577 or FAK antibodies. (c) Lysates prepared as in (a) were incubated with GST-PBD (to enrich for GTP-bound active Cdc42 and Rac1). Elutes and total lysates were subsequently immunoblotted with antibodies against Cdc42 and Rac1. (d) CT-26 Vec, CT-26 SH3BGRL, CHO Vec and CHO SH3BGRL cells were transfected with FAK-specific siRNA, where indicated, for 48 h and lysed. Lysates were immunoblotted with the various antibodies listed. GAPDH was served as a loading control. The averaged relative protein expression level is quantified and shown under the immediate panels.
    Figure Legend Snippet: Figure 3. mSH3BGRL activates MAPK and AKT pathways in an FAK-dependent manner. (a) Lysates from stable cell lines were incubated with GST-Raf to enrich for GTP-bound active Ras. Eluates and total lysates were subsequently immunoblotted with various Ras/MAPK pathway-specific antibodies. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) served as a loading control. (b) Lysates from (a) were immunoblotted with anti-p-FAK Y576/577 or FAK antibodies. (c) Lysates prepared as in (a) were incubated with GST-PBD (to enrich for GTP-bound active Cdc42 and Rac1). Elutes and total lysates were subsequently immunoblotted with antibodies against Cdc42 and Rac1. (d) CT-26 Vec, CT-26 SH3BGRL, CHO Vec and CHO SH3BGRL cells were transfected with FAK-specific siRNA, where indicated, for 48 h and lysed. Lysates were immunoblotted with the various antibodies listed. GAPDH was served as a loading control. The averaged relative protein expression level is quantified and shown under the immediate panels.

    Techniques Used: Stable Transfection, Incubation, Control, Transfection, Expressing

    Figure 4. Knockdown of c-Src abrogates mSH3BGRL-induced metastasis in nude mice. (a) Four independent pools of CT-26 SH3BGRL cells stably expressing c-Src-specific shRNA (SH3BGRL-SrcKD 1–4) were analyzed for the expression of c-Src compared with a scrambled control (SH3BGRL-scr). glyceraldehyde 3-phosphate dehydrogenase (GAPDH) served as a loading control. (b) Lysates from exponentially growing stable cells (SH3BGRL-SrcKD is a combined pool from all four clones in (a)) were immunoblotted with various antibodies. GAPDH served as a loading control. The averaged relative protein expression level in (a) and (b) is quantified and shown under the immediate panels. (c) In total, 1 × 106 CT-26 SH3BGRL or CT-26 SH3BGRL-SrcKD cells were injected intravenously into the tail vein of nude mice. After 14 days, mice were killed and their lungs were photographed and scored for metastatic tumor nodules (mean ± s.d., n = 4, ***Po0.001).
    Figure Legend Snippet: Figure 4. Knockdown of c-Src abrogates mSH3BGRL-induced metastasis in nude mice. (a) Four independent pools of CT-26 SH3BGRL cells stably expressing c-Src-specific shRNA (SH3BGRL-SrcKD 1–4) were analyzed for the expression of c-Src compared with a scrambled control (SH3BGRL-scr). glyceraldehyde 3-phosphate dehydrogenase (GAPDH) served as a loading control. (b) Lysates from exponentially growing stable cells (SH3BGRL-SrcKD is a combined pool from all four clones in (a)) were immunoblotted with various antibodies. GAPDH served as a loading control. The averaged relative protein expression level in (a) and (b) is quantified and shown under the immediate panels. (c) In total, 1 × 106 CT-26 SH3BGRL or CT-26 SH3BGRL-SrcKD cells were injected intravenously into the tail vein of nude mice. After 14 days, mice were killed and their lungs were photographed and scored for metastatic tumor nodules (mean ± s.d., n = 4, ***Po0.001).

    Techniques Used: Knockdown, Stable Transfection, Expressing, shRNA, Control, Clone Assay, Injection

    Related Articles

    Knockdown:

    Article Title: Dual-faced SH3BGRL: oncogenic in mice, tumor suppressive in humans
    Article Snippet: .. For knockdown of c-Src in CT-26 cells overexpressing SH3BGRL, four shRNA constructs against mouse Src (OriGene, Rockville, MD, USA; cat. no. TG514248) were transfected to generate stable cell pools using 1 μg/ml puromycin selection for 3–4 weeks. .. Similarly, two shRNA constructs against hSH3BGRL (OriGene; cat. no. TG309466) were transfected to establish MDA-MB-231 hSH3BGRL stable knockdown cell pools.

    Article Title: Dual-faced SH3BGRL: oncogenic in mice, tumor suppressive in humans.
    Article Snippet: .. For knockdown of c-Src in CT-26 cells overexpressing SH3BGRL, four shRNA constructs against mouse Src (OriGene, Rockville, MD, USA; cat. no. TG514248) were transfected to generate stable cell pools using 1 μg/ml puromycin selection for 3–4 weeks. .. Similarly, two shRNA constructs against hSH3BGRL (OriGene; cat. no. TG309466) were transfected to establish MDA-MB-231 hSH3BGRL stable knockdown cell pools.

    shRNA:

    Article Title: Dual-faced SH3BGRL: oncogenic in mice, tumor suppressive in humans
    Article Snippet: .. For knockdown of c-Src in CT-26 cells overexpressing SH3BGRL, four shRNA constructs against mouse Src (OriGene, Rockville, MD, USA; cat. no. TG514248) were transfected to generate stable cell pools using 1 μg/ml puromycin selection for 3–4 weeks. .. Similarly, two shRNA constructs against hSH3BGRL (OriGene; cat. no. TG309466) were transfected to establish MDA-MB-231 hSH3BGRL stable knockdown cell pools.

    Article Title: Dual-faced SH3BGRL: oncogenic in mice, tumor suppressive in humans.
    Article Snippet: .. For knockdown of c-Src in CT-26 cells overexpressing SH3BGRL, four shRNA constructs against mouse Src (OriGene, Rockville, MD, USA; cat. no. TG514248) were transfected to generate stable cell pools using 1 μg/ml puromycin selection for 3–4 weeks. .. Similarly, two shRNA constructs against hSH3BGRL (OriGene; cat. no. TG309466) were transfected to establish MDA-MB-231 hSH3BGRL stable knockdown cell pools.

    Construct:

    Article Title: Dual-faced SH3BGRL: oncogenic in mice, tumor suppressive in humans
    Article Snippet: .. For knockdown of c-Src in CT-26 cells overexpressing SH3BGRL, four shRNA constructs against mouse Src (OriGene, Rockville, MD, USA; cat. no. TG514248) were transfected to generate stable cell pools using 1 μg/ml puromycin selection for 3–4 weeks. .. Similarly, two shRNA constructs against hSH3BGRL (OriGene; cat. no. TG309466) were transfected to establish MDA-MB-231 hSH3BGRL stable knockdown cell pools.

    Article Title: Dual-faced SH3BGRL: oncogenic in mice, tumor suppressive in humans.
    Article Snippet: .. For knockdown of c-Src in CT-26 cells overexpressing SH3BGRL, four shRNA constructs against mouse Src (OriGene, Rockville, MD, USA; cat. no. TG514248) were transfected to generate stable cell pools using 1 μg/ml puromycin selection for 3–4 weeks. .. Similarly, two shRNA constructs against hSH3BGRL (OriGene; cat. no. TG309466) were transfected to establish MDA-MB-231 hSH3BGRL stable knockdown cell pools.

    Transfection:

    Article Title: Dual-faced SH3BGRL: oncogenic in mice, tumor suppressive in humans
    Article Snippet: .. For knockdown of c-Src in CT-26 cells overexpressing SH3BGRL, four shRNA constructs against mouse Src (OriGene, Rockville, MD, USA; cat. no. TG514248) were transfected to generate stable cell pools using 1 μg/ml puromycin selection for 3–4 weeks. .. Similarly, two shRNA constructs against hSH3BGRL (OriGene; cat. no. TG309466) were transfected to establish MDA-MB-231 hSH3BGRL stable knockdown cell pools.

    Article Title: Dual-faced SH3BGRL: oncogenic in mice, tumor suppressive in humans.
    Article Snippet: .. For knockdown of c-Src in CT-26 cells overexpressing SH3BGRL, four shRNA constructs against mouse Src (OriGene, Rockville, MD, USA; cat. no. TG514248) were transfected to generate stable cell pools using 1 μg/ml puromycin selection for 3–4 weeks. .. Similarly, two shRNA constructs against hSH3BGRL (OriGene; cat. no. TG309466) were transfected to establish MDA-MB-231 hSH3BGRL stable knockdown cell pools.

    Stable Transfection:

    Article Title: Dual-faced SH3BGRL: oncogenic in mice, tumor suppressive in humans
    Article Snippet: .. For knockdown of c-Src in CT-26 cells overexpressing SH3BGRL, four shRNA constructs against mouse Src (OriGene, Rockville, MD, USA; cat. no. TG514248) were transfected to generate stable cell pools using 1 μg/ml puromycin selection for 3–4 weeks. .. Similarly, two shRNA constructs against hSH3BGRL (OriGene; cat. no. TG309466) were transfected to establish MDA-MB-231 hSH3BGRL stable knockdown cell pools.

    Article Title: Dual-faced SH3BGRL: oncogenic in mice, tumor suppressive in humans.
    Article Snippet: .. For knockdown of c-Src in CT-26 cells overexpressing SH3BGRL, four shRNA constructs against mouse Src (OriGene, Rockville, MD, USA; cat. no. TG514248) were transfected to generate stable cell pools using 1 μg/ml puromycin selection for 3–4 weeks. .. Similarly, two shRNA constructs against hSH3BGRL (OriGene; cat. no. TG309466) were transfected to establish MDA-MB-231 hSH3BGRL stable knockdown cell pools.

    Selection:

    Article Title: Dual-faced SH3BGRL: oncogenic in mice, tumor suppressive in humans
    Article Snippet: .. For knockdown of c-Src in CT-26 cells overexpressing SH3BGRL, four shRNA constructs against mouse Src (OriGene, Rockville, MD, USA; cat. no. TG514248) were transfected to generate stable cell pools using 1 μg/ml puromycin selection for 3–4 weeks. .. Similarly, two shRNA constructs against hSH3BGRL (OriGene; cat. no. TG309466) were transfected to establish MDA-MB-231 hSH3BGRL stable knockdown cell pools.

    Article Title: Dual-faced SH3BGRL: oncogenic in mice, tumor suppressive in humans.
    Article Snippet: .. For knockdown of c-Src in CT-26 cells overexpressing SH3BGRL, four shRNA constructs against mouse Src (OriGene, Rockville, MD, USA; cat. no. TG514248) were transfected to generate stable cell pools using 1 μg/ml puromycin selection for 3–4 weeks. .. Similarly, two shRNA constructs against hSH3BGRL (OriGene; cat. no. TG309466) were transfected to establish MDA-MB-231 hSH3BGRL stable knockdown cell pools.



    Similar Products

    shrna constructs against mouse src  (OriGene)
    90
    OriGene shrna constructs against mouse src
    Figure 3. mSH3BGRL activates MAPK and AKT pathways in an FAK-dependent manner. (a) Lysates from stable cell lines were incubated with GST-Raf to enrich for GTP-bound active Ras. Eluates and total lysates were subsequently immunoblotted with various Ras/MAPK pathway-specific antibodies. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) served as a loading control. (b) Lysates from (a) were immunoblotted with anti-p-FAK Y576/577 or FAK antibodies. (c) Lysates prepared as in (a) were incubated with GST-PBD (to enrich for GTP-bound active Cdc42 and Rac1). Elutes and total lysates were subsequently immunoblotted with antibodies against Cdc42 and Rac1. (d) CT-26 Vec, <t>CT-26</t> <t>SH3BGRL,</t> CHO Vec and CHO SH3BGRL cells were transfected with FAK-specific <t>siRNA,</t> where indicated, for 48 h and lysed. Lysates were immunoblotted with the various antibodies listed. GAPDH was served as a loading control. The averaged relative protein expression level is quantified and shown under the immediate panels.
    Shrna Constructs Against Mouse Src, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/shrna+constructs+against+mouse+src/Src+Mouse+shRNA+Plasmid/pm26455318-157-10-15
    Average 90 stars, based on 1 article reviews
    shrna constructs against mouse src - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Figure 3. mSH3BGRL activates MAPK and AKT pathways in an FAK-dependent manner. (a) Lysates from stable cell lines were incubated with GST-Raf to enrich for GTP-bound active Ras. Eluates and total lysates were subsequently immunoblotted with various Ras/MAPK pathway-specific antibodies. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) served as a loading control. (b) Lysates from (a) were immunoblotted with anti-p-FAK Y576/577 or FAK antibodies. (c) Lysates prepared as in (a) were incubated with GST-PBD (to enrich for GTP-bound active Cdc42 and Rac1). Elutes and total lysates were subsequently immunoblotted with antibodies against Cdc42 and Rac1. (d) CT-26 Vec, CT-26 SH3BGRL, CHO Vec and CHO SH3BGRL cells were transfected with FAK-specific siRNA, where indicated, for 48 h and lysed. Lysates were immunoblotted with the various antibodies listed. GAPDH was served as a loading control. The averaged relative protein expression level is quantified and shown under the immediate panels.

    Journal: Oncogene

    Article Title: Dual-faced SH3BGRL: oncogenic in mice, tumor suppressive in humans.

    doi: 10.1038/onc.2015.391

    Figure Lengend Snippet: Figure 3. mSH3BGRL activates MAPK and AKT pathways in an FAK-dependent manner. (a) Lysates from stable cell lines were incubated with GST-Raf to enrich for GTP-bound active Ras. Eluates and total lysates were subsequently immunoblotted with various Ras/MAPK pathway-specific antibodies. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) served as a loading control. (b) Lysates from (a) were immunoblotted with anti-p-FAK Y576/577 or FAK antibodies. (c) Lysates prepared as in (a) were incubated with GST-PBD (to enrich for GTP-bound active Cdc42 and Rac1). Elutes and total lysates were subsequently immunoblotted with antibodies against Cdc42 and Rac1. (d) CT-26 Vec, CT-26 SH3BGRL, CHO Vec and CHO SH3BGRL cells were transfected with FAK-specific siRNA, where indicated, for 48 h and lysed. Lysates were immunoblotted with the various antibodies listed. GAPDH was served as a loading control. The averaged relative protein expression level is quantified and shown under the immediate panels.

    Article Snippet: For knockdown of c-Src in CT-26 cells overexpressing SH3BGRL, four shRNA constructs against mouse Src (OriGene, Rockville, MD, USA; cat. no. TG514248) were transfected to generate stable cell pools using 1 μg/ml puromycin selection for 3–4 weeks.

    Techniques: Stable Transfection, Incubation, Control, Transfection, Expressing

    Figure 4. Knockdown of c-Src abrogates mSH3BGRL-induced metastasis in nude mice. (a) Four independent pools of CT-26 SH3BGRL cells stably expressing c-Src-specific shRNA (SH3BGRL-SrcKD 1–4) were analyzed for the expression of c-Src compared with a scrambled control (SH3BGRL-scr). glyceraldehyde 3-phosphate dehydrogenase (GAPDH) served as a loading control. (b) Lysates from exponentially growing stable cells (SH3BGRL-SrcKD is a combined pool from all four clones in (a)) were immunoblotted with various antibodies. GAPDH served as a loading control. The averaged relative protein expression level in (a) and (b) is quantified and shown under the immediate panels. (c) In total, 1 × 106 CT-26 SH3BGRL or CT-26 SH3BGRL-SrcKD cells were injected intravenously into the tail vein of nude mice. After 14 days, mice were killed and their lungs were photographed and scored for metastatic tumor nodules (mean ± s.d., n = 4, ***Po0.001).

    Journal: Oncogene

    Article Title: Dual-faced SH3BGRL: oncogenic in mice, tumor suppressive in humans.

    doi: 10.1038/onc.2015.391

    Figure Lengend Snippet: Figure 4. Knockdown of c-Src abrogates mSH3BGRL-induced metastasis in nude mice. (a) Four independent pools of CT-26 SH3BGRL cells stably expressing c-Src-specific shRNA (SH3BGRL-SrcKD 1–4) were analyzed for the expression of c-Src compared with a scrambled control (SH3BGRL-scr). glyceraldehyde 3-phosphate dehydrogenase (GAPDH) served as a loading control. (b) Lysates from exponentially growing stable cells (SH3BGRL-SrcKD is a combined pool from all four clones in (a)) were immunoblotted with various antibodies. GAPDH served as a loading control. The averaged relative protein expression level in (a) and (b) is quantified and shown under the immediate panels. (c) In total, 1 × 106 CT-26 SH3BGRL or CT-26 SH3BGRL-SrcKD cells were injected intravenously into the tail vein of nude mice. After 14 days, mice were killed and their lungs were photographed and scored for metastatic tumor nodules (mean ± s.d., n = 4, ***Po0.001).

    Article Snippet: For knockdown of c-Src in CT-26 cells overexpressing SH3BGRL, four shRNA constructs against mouse Src (OriGene, Rockville, MD, USA; cat. no. TG514248) were transfected to generate stable cell pools using 1 μg/ml puromycin selection for 3–4 weeks.

    Techniques: Knockdown, Stable Transfection, Expressing, shRNA, Control, Clone Assay, Injection